Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $34.57

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have earned an average rating of “Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $34.57.

A number of brokerages recently issued reports on DAWN. Bank of America decreased their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. JPMorgan Chase & Co. lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Wedbush restated an “outperform” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Finally, HC Wainwright dropped their target price on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday, February 26th.

Insider Activity at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Virtus ETF Advisers LLC grew its position in shares of Day One Biopharmaceuticals by 7.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company’s stock worth $346,000 after acquiring an additional 1,805 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Day One Biopharmaceuticals by 5.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company’s stock valued at $454,000 after purchasing an additional 1,894 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Day One Biopharmaceuticals in the 4th quarter valued at about $27,000. China Universal Asset Management Co. Ltd. lifted its stake in Day One Biopharmaceuticals by 11.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock valued at $271,000 after purchasing an additional 2,180 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth $31,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Trading Up 1.5 %

NASDAQ:DAWN opened at $8.79 on Friday. The stock has a 50 day moving average of $11.52 and a two-hundred day moving average of $13.09. Day One Biopharmaceuticals has a 12 month low of $7.88 and a 12 month high of $18.07. The firm has a market cap of $890.91 million, a P/E ratio of -8.53 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. On average, research analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.